Validation of DNA Methylation Markers for the Universal and Site-Specific Guided Cancer Detection (the VANGUARD Study)
Mayo Clinic
Summary
This study explores the potential value of a new blood test approach for early detection of cancer.
Description
PRIMARY OBJECTIVES: I. Validate candidate universal and site-specific MDMs in DNA extracted from formalin-fixed paraffin embedded primary tumor and control specimens. II. Test MDM-based models for detection of the top 16 most lethal human cancers using a non-invasive biological medium, specifically blood. III. Assess feasibility for detection of cancers using urine samples to assay MDMs, RNA or protein in cell free or extra-cellular vesicles; patients may be the same or unique individuals from Aim 1 and 2. OUTLINE: This is an observational study. Patients undergo blood, urine, and/or resi…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Aim 1 Tissue * Cases: * Patient has a biopsy confirmed diagnosis of target histology * Tissue samples from synchronous or metachronous primary cancers may be used as long as they are clearly of a different target organ. * Tumors from patients with an underlying genetic disorder pre-disposing to cancer may be included as long as they are stratified from those without * Controls: * Patient does not have the diagnosis of target histology * Aim 2 Blood * Cases: * Patient has a biopsy confirmed diagnosis of target histology or radiographic crite…
Interventions
- OtherNon-Interventional Study
Non-interventional study
Location
- Mayo Clinic in RochesterRochester, Minnesota